Zimmer Biomet Holdings, Inc. ZBH

Zacks Investment Research 5 nov

Zimmer Biomet (ZBH), a musculoskeletal healthcare company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The stock has gained 24.5% over the past four weeks with a Momentum Style Score of A, driven by two analyst earnings estimate revisions higher for fiscal 2026.

GlobeNewswire Inc. 4 nov

The ANZ dental implants market is valued at USD 266.0 million in 2025 and is projected to reach USD 393.0 million by 2033, growing at a 5.0% CAGR. Growth is driven by aging populations, increased demand for prosthetics, and technological advances in implant materials. However, high treatment costs remain a significant barrier to market expansion, with 28% of Australians delaying dental care due to affordability concerns.

Zacks Investment Research 4 nov

Zimmer Biomet reported Q3 2026 earnings of $1.90 per share, slightly beating consensus estimates of $1.89, with revenues of $2.06 billion exceeding expectations by 0.81%. However, the stock has underperformed the S&P 500 year-to-date, gaining 7.9% versus the market's 10.6%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research 29 oct

Zimmer Biomet is set to report Q3 2026 results on Nov. 4 with revenues expected to grow 2.2% to $2.05 billion, while EPS is projected to decline 0.5% year-over-year. The company faces headwinds from legacy implant phaseouts and international market pressures, particularly in China, though new product adoption and the Paragon 28 acquisition are expected to provide growth support across multiple segments.

Zacks Investment Research 12 oct

Zimmer Biomet (ZBH) is identified as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company trades at a P/E ratio of 11.98, below its industry average of 15.93, and demonstrates solid valuation metrics across P/B and P/CF ratios, suggesting it may be undervalued relative to its earnings outlook.